Form 8-K - Current report:
SEC Accession No. 0001193125-25-051532
Filing Date
2025-03-11
Accepted
2025-03-11 08:54:12
Documents
17
Period of Report
2025-03-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d897420d8k.htm   iXBRL 8-K 29818
2 EX-1.1 d897420dex11.htm EX-1.1 197666
3 EX-5.1 d897420dex51.htm EX-5.1 12168
7 GRAPHIC g897420g0305235137713.jpg GRAPHIC 1649
8 GRAPHIC g897420g0305235525226.jpg GRAPHIC 5595
  Complete submission text file 0001193125-25-051532.txt   437328

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA xlo-20250311.xsd EX-101.SCH 2836
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE xlo-20250311_lab.xml EX-101.LAB 18738
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xlo-20250311_pre.xml EX-101.PRE 11699
19 EXTRACTED XBRL INSTANCE DOCUMENT d897420d8k_htm.xml XML 3765
Mailing Address 828 WINTER STREET WALTHAM MA 02451
Business Address 828 WINTER STREET WALTHAM MA 02451 617-833-1027
Xilio Therapeutics, Inc. (Filer) CIK: 0001840233 (see all company filings)

EIN.: 851623397 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40925 | Film No.: 25725985
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)